HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Raises Price Target to $63
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Janux Therapeutics (NASDAQ:JANX) and raises the price target from $50 to $63.
May 13, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Janux Therapeutics' price target was raised from $50 to $63 by HC Wainwright & Co., maintaining a Buy rating.
A raised price target by a reputable analyst firm typically signals a positive outlook on the stock, suggesting potential upside. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100